We were all excited thinking the MERCK recall of Vioxx might set off more intensive testing proceedures across the medical industry, but sadly ERES continues to underperform. The real money in the testing field is determining the interaction protocols of new drugs. I'm sadly disappointed ERES hasn't diversified into this very lucrative market. ERES has both the professional staffing as well as laboratories going to waste that would bring in millions of new revenue, if only the diversified minimally.
I'd like to hear from actualy ERES employess about my suggestion please.